MCID: ALP061
MIFTS: 40

Alopecia, Androgenetic, 1

Categories: Rare diseases

Aliases & Classifications for Alopecia, Androgenetic, 1

MalaCards integrated aliases for Alopecia, Androgenetic, 1:

Name: Alopecia, Androgenetic, 1 54 29 13 38
Androgenetic Alopecia 38 50 25 69
Androgenic Alopecia 50 25
Female Pattern Baldness 25
Female Pattern Alopecia 69
Male Pattern Alopecia 25
Male Pattern Baldness 25
Alopecia Androgenetic 52
Pattern Baldness 25

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant in males
recessive in females


HPO:

32
alopecia, androgenetic, 1:
Inheritance sex-limited autosomal dominant


Classifications:



External Ids:

OMIM 54 109200
SNOMED-CT via HPO 65 278040002 56317004

Summaries for Alopecia, Androgenetic, 1

OMIM : 54
Androgenetic alopecia is characterized by a loss of hair from the scalp that follows a defined pattern (Hamilton, 1951). It occurs in women as well as in men. It is caused by a shortening of the anagen (growth) phase and miniaturization of the hair follicle, which results in the formation of progressively thinner, shorter hair (Bergfeld, 1995). In men, the condition is often referred to as male pattern baldness (MPB) and appears to be androgen-dependent (Hamilton, 1942). The condition is hereditary, and follows a pattern that may be consistent with an autosomal dominant trait (Osborn, 1916). Linkage evidence for an autosomal locus on 3q26 (AGA1) has been identified (Hillmer et al., 2008). See 300710 (AGA2) for a discussion of X linkage of androgenetic alopecia. A third locus has been found on chromosome 20p11 (AGA3; 612421). (109200)

MalaCards based summary : Alopecia, Androgenetic, 1, also known as androgenetic alopecia, is related to prostate cancer and alopecia, androgenetic, 3, and has symptoms including alopecia An important gene associated with Alopecia, Androgenetic, 1 is AFA1 (Alopecia, Androgenetic), and among its related pathways/superpathways are Transcription Androgen Receptor nuclear signaling and Metabolism of steroid hormones. The drugs Minoxidil and Finasteride have been mentioned in the context of this disorder. Affiliated tissues include testes and prostate, and related phenotypes are endocrine/exocrine gland and reproductive system

Genetics Home Reference : 25 Androgenetic alopecia is a common form of hair loss in both men and women. In men, this condition is also known as male-pattern baldness. Hair is lost in a well-defined pattern, beginning above both temples. Over time, the hairline recedes to form a characteristic "M" shape. Hair also thins at the crown (near the top of the head), often progressing to partial or complete baldness.

NIH Rare Diseases : 50 androgenetic alopecia is a common form of hair loss in both men and women. in men, hair is usually lost in a well-defined pattern, beginning above both temples and is usually referred to as male-pattern baldness. over time, the hairline recedes to form a characteristic 'm' shape. hair also thins near the top of the head, often progressing to partial or complete baldness. the pattern of hair loss in women differs from men (female pattern hair loss). in women, the hair becomes thinner all over the head, and the hairline does not recede. androgenetic alopecia in women rarely leads to total baldness. a variety of genetic and environmental factors likely play a role in causing this condition. mutations in the ar gene have also been associated with androgenetic alopecia. last updated: 8/19/2011

Related Diseases for Alopecia, Androgenetic, 1

Diseases in the Alopecia, Androgenetic, 1 family:

Alopecia, Androgenetic, 3 Alopecia, Androgenetic, 2

Diseases related to Alopecia, Androgenetic, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 64)
id Related Disease Score Top Affiliating Genes
1 prostate cancer 27.0 AR CFLAR CYP19A1 SHBG SRD5A1 SRD5A2
2 alopecia, androgenetic, 3 12.0
3 alopecia, androgenetic, 2 12.0
4 marie unna congenital hypotrichosis 11.1
5 alopecia 11.1
6 androgenic alopecia 11.0
7 hypotrichosis simplex 11.0
8 hypotrichosis 1 11.0
9 ulceroglandular tularemia 10.4 AR SHBG
10 alopecia areata 10.4
11 polyneuropathy 10.4 CYP19A1 SHBG
12 8p23.1 duplication syndrome 10.4 SRD5A1 SRD5A2
13 prostatitis 10.3
14 osteogenesis imperfecta 10.3 AR CYP19A1
15 telogen effluvium 10.3
16 acute thyroiditis 10.2 CYP19A1 SHBG
17 vaginal discharge 10.2 AR SHBG SRD5A2
18 acne 10.2
19 esophagus sarcoma 10.2 AR CYP19A1
20 glioblastoma proneural subtype 10.1 AR CYP19A1 SHBG
21 condrodisplasia punctata rizomélica 10.1 AR CYP19A1 SHBG
22 ocular hypotension 10.1 CYP19A1 CYP21A2
23 porokeratosis 10.1 CYP19A1 SHBG
24 lichen planopilaris 10.1
25 capillary disease 10.1 AR CYP19A1 SHBG
26 diabetes mellitus, insulin-resistant, with acanthosis nigricans 10.1 AR SHBG STS
27 intraventricular meningioma 10.1 AR CYP19A1 SRD5A2
28 avoidant personality disorder 10.1 AR CYP19A1 SHBG
29 endometriosis 10.0 AR SHBG SRD5A1
30 heart disease 10.0
31 coronary artery disease 10.0
32 artery disease 10.0
33 pepck 1 deficiency 10.0 AR SRD5A1 SRD5A2
34 weill-marchesani syndrome 10.0 CYP19A1 CYP21A2
35 frontal fibrosing alopecia 10.0
36 hyperandrogenism 10.0
37 dermatitis 10.0
38 psoriasis 10.0
39 tooth disease 9.9 AR SRD5A1 SRD5A2
40 pelvic muscle wasting 9.9 CYP19A1 CYP21A2 SHBG
41 liver sarcoma 9.8 CYP19A1 CYP21A2
42 ichthyosis vulgaris 9.8
43 personality disorder 9.8
44 breast cancer 9.8
45 ichthyosis 9.8
46 endotheliitis 9.8
47 contact dermatitis 9.8
48 atopic dermatitis 9.8
49 adrenoleukodystrophy 9.8
50 hermaphroditism 9.8

Graphical network of the top 20 diseases related to Alopecia, Androgenetic, 1:



Diseases related to Alopecia, Androgenetic, 1

Symptoms & Phenotypes for Alopecia, Androgenetic, 1

Symptoms via clinical synopsis from OMIM:

54

Hair:
early baldness


Clinical features from OMIM:

109200

Human phenotypes related to Alopecia, Androgenetic, 1:

32
id Description HPO Frequency HPO Source Accession
1 alopecia 32 HP:0001596

MGI Mouse Phenotypes related to Alopecia, Androgenetic, 1:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.5 AR CFLAR CYP19A1 SRD5A1 SRD5A2 TGFB2
2 reproductive system MP:0005389 9.1 AR CYP19A1 SRD5A1 SRD5A2 TGFB2 XIAP

Drugs & Therapeutics for Alopecia, Androgenetic, 1

Drugs for Alopecia, Androgenetic, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Minoxidil Approved Phase 3,Phase 1,Phase 2 38304-91-5 4201
2
Finasteride Approved Phase 3,Phase 1,Phase 2 98319-26-7 57363
3
Dutasteride Approved, Investigational Phase 3,Phase 1 164656-23-9 152945 6918296
4 Antihypertensive Agents Phase 3,Phase 1,Phase 2
5 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
6 Vasodilator Agents Phase 3,Phase 1,Phase 2
7 5-alpha Reductase Inhibitors Phase 3,Phase 1,Phase 2
8 Hormone Antagonists Phase 3,Phase 1,Phase 2
9 Hormones Phase 3,Phase 1,Phase 2
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2
11 Steroid Synthesis Inhibitors Phase 3,Phase 1,Phase 2
12
Nitric Oxide Approved Phase 1, Phase 2 10102-43-9 145068
13
Bimatoprost Approved, Investigational Phase 2,Phase 1 155206-00-1 5311027
14
Vitamin C Approved, Nutraceutical Phase 1, Phase 2 50-81-7 5785 54670067
15
Maleic acid Experimental Phase 1, Phase 2 110-16-7 444266
16 HIV Protease Inhibitors Phase 2
17
protease inhibitors Phase 2
18 Proteasome Inhibitors Phase 2
19 Anti-Asthmatic Agents Phase 1, Phase 2
20 Antioxidants Phase 1, Phase 2
21 Autonomic Agents Phase 1, Phase 2
22 Bronchodilator Agents Phase 1, Phase 2
23 Endothelium-Dependent Relaxing Factors Phase 1, Phase 2
24 Neurotransmitter Agents Phase 1, Phase 2
25 Peripheral Nervous System Agents Phase 1, Phase 2
26 Protective Agents Phase 1, Phase 2
27 Respiratory System Agents Phase 1, Phase 2
28 Mitogens Phase 1, Phase 2
29
Ethanol Approved Phase 1 64-17-5 702
30
Methyltestosterone Approved Phase 1 58-18-4 6010
31
Testosterone Approved, Investigational Phase 1 58-22-0 6013
32 Anesthetics Phase 1
33 Anabolic Agents Phase 1
34 Androgens Phase 1
35 Antineoplastic Agents, Hormonal Phase 1
36 Estrogens Phase 1
37 Estrogens, Conjugated (USP) Phase 1
38 Micronutrients Phase 1
39 Testosterone 17 beta-cypionate Phase 1
40
Testosterone enanthate Phase 1 315-37-7 9416
41 Testosterone undecanoate Phase 1
42 Trace Elements Phase 1
43 Vitamins Phase 1
44 Calcium, Dietary
45 Plasminogen Activator Inhibitor 1
46 Citrate Nutraceutical
47
Citric Acid Nutraceutical, Vet_approved 77-92-9 311

Interventional clinical trials:

(show all 42)

id Name Status NCT ID Phase Drugs
1 Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Active, not recruiting NCT02999737 Phase 4
2 Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients Unknown status NCT01655108 Phase 3 Minoxidil;Saline
3 Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
4 Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
5 A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Completed NCT00151515 Phase 3 minoxidil
6 Clinical Trial in Females for Female Pattern Hair Loss Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
7 A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
8 Clinical Trial in Females With Female Pattern Hair Loss Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
9 Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia Active, not recruiting NCT03004469 Phase 3 P-3074;Finasteride;Vehicle
10 Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Unknown status NCT00471510 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
11 Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia Unknown status NCT01501617 Phase 1, Phase 2
12 A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia Unknown status NCT01643629 Phase 1, Phase 2
13 Study To Determine Safety & Efficacy Of Autologous Human Platelet Lysate in Androgenetic Alopecia After Hair Transplant Unknown status NCT01644422 Phase 1, Phase 2
14 Efficacy and Safety Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Androgenetic Alopecia Unknown status NCT01650272 Phase 1, Phase 2 5% MInoxidil milky lotion;5% Minoxidil solution
15 Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia Unknown status NCT01347957 Phase 1, Phase 2
16 A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) Completed NCT01904721 Phase 2 Bimatoprost Solution 1;Bimatoprost Solution 2;Bimatoprost Vehicle
17 Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application Completed NCT02280603 Phase 1, Phase 2 DA-4001C;5% minoxidil
18 Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia Completed NCT01286649 Phase 1, Phase 2
19 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451021 Phase 2
20 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013) Completed NCT01451073 Phase 2
21 Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia Completed NCT01319370 Phase 2 Minoxidil;vehicle of 5% Minoxidil topical foam
22 A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss Completed NCT01900041 Phase 2 Pantovigar;Minoxidil 2% only
23 A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing Completed NCT02503137 Phase 2 Topical SM04554 solution;Topical Vehicle solution
24 A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Completed NCT02275351 Phase 2 SM04554;Vehicle
25 Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Completed NCT00418730 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
26 Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males Recruiting NCT02781311 Phase 2 setipiprant;placebo
27 AGA Biocellular Stem/Stromal Hair Regenerative Study Recruiting NCT02849470 Phase 1, Phase 2
28 The Effect of Platelet-rich Plasma in Subjects With Androgenetic Alopecia Not yet recruiting NCT03048461 Phase 2 Placebo
29 Split Wound Comparison of Trichophytic Closure Techniques for Donor Site in Hair Transplantation Unknown status NCT01655602 Phase 1
30 Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia Unknown status NCT02154503 Phase 1
31 Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia Completed NCT02848300 Phase 1 Bimatoprost 1% Formulation A;Bimatoprost 1% Formulation B
32 Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia Completed NCT01052870 Phase 1 Finasteride
33 Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia Completed NCT01189279 Phase 1 bimatoprost Formulation A;bimatoprost Formulation B;bimatoprost Formulation C
34 Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers Completed NCT01929330 Phase 1 GI198745 0.1 mg;GI198745 0.5 mg
35 Photosensitization Study in Androgenetic Alopecia Completed NCT02791243 Phase 1 Finasteride 0.25%;Placebo for Finasteride 0.25%;Negative Control
36 Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia Not yet recruiting NCT02824380 Phase 1 DA-4001 H;DA-4001 L
37 Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA) Terminated NCT02676310 Phase 1 Bimatoprost
38 Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia Unknown status NCT02393040
39 Effect of PRP on the Therapy for Hair Growth Completed NCT02087319
40 PAI-1 Expression in Non-scarring Hair Loss Recruiting NCT02548689
41 Point-of-Care Adipose-derived Cells for Hair Growth Recruiting NCT02729415 Early Phase 1
42 Minoxidil Response Testing in Males With Androgenetic Alopecia Active, not recruiting NCT02198261 5% minoxidil topical foam

Search NIH Clinical Center for Alopecia, Androgenetic, 1

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Alopecia, Androgenetic, 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Alopecia, Androgenetic, 1:
RepliCel Hair-01 (RCH-01), hair follicle-derived mesenchymal stem cells for treatment of androgenetic alopecia
Embryonic/Adult Cultured Cells Related to Alopecia, Androgenetic, 1:
Hair follicle mesenchymal stem cells (RepliCel Hair-01)

Genetic Tests for Alopecia, Androgenetic, 1

Genetic tests related to Alopecia, Androgenetic, 1:

id Genetic test Affiliating Genes
1 Alopecia, Androgenetic, 1 29

Anatomical Context for Alopecia, Androgenetic, 1

MalaCards organs/tissues related to Alopecia, Androgenetic, 1:

39
Testes, Prostate

Publications for Alopecia, Androgenetic, 1

Variations for Alopecia, Androgenetic, 1

Expression for Alopecia, Androgenetic, 1

Search GEO for disease gene expression data for Alopecia, Androgenetic, 1.

Pathways for Alopecia, Androgenetic, 1

GO Terms for Alopecia, Androgenetic, 1

Cellular components related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.65 CYP19A1 CYP21A2 SRD5A1 SRD5A2 STS
2 endoplasmic reticulum membrane GO:0005789 9.55 CYP19A1 CYP21A2 SRD5A1 SRD5A2 STS
3 organelle membrane GO:0031090 9.13 CYP21A2 SRD5A1 SRD5A2
4 cell body fiber GO:0070852 8.62 SRD5A1 SRD5A2

Biological processes related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

(show all 22)
id Name GO ID Score Top Affiliating Genes
1 steroid metabolic process GO:0008202 9.67 CYP21A2 SRD5A1 SRD5A2 STS
2 cellular response to estradiol stimulus GO:0071392 9.61 CFLAR SRD5A1
3 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 9.6 AR CFLAR
4 cellular response to dexamethasone stimulus GO:0071549 9.59 CFLAR SRD5A1
5 sterol metabolic process GO:0016125 9.58 CYP19A1 CYP21A2
6 male genitalia development GO:0030539 9.58 SRD5A1 SRD5A2
7 response to testosterone GO:0033574 9.58 CFLAR SRD5A1 SRD5A2
8 uterus development GO:0060065 9.57 CYP19A1 TGFB2
9 hypothalamus development GO:0021854 9.56 SRD5A1 SRD5A2
10 male gonad development GO:0008584 9.56 AR SRD5A1 SRD5A2 TGFB2
11 androgen biosynthetic process GO:0006702 9.55 SRD5A1 SRD5A2
12 progesterone metabolic process GO:0042448 9.54 SRD5A1 SRD5A2
13 cellular response to testosterone stimulus GO:0071394 9.52 AR SRD5A1
14 prostate gland growth GO:0060736 9.51 AR CYP19A1
15 sex differentiation GO:0007548 9.5 AR SRD5A1 SRD5A2
16 response to follicle-stimulating hormone GO:0032354 9.49 SRD5A1 SRD5A2
17 testosterone biosynthetic process GO:0061370 9.48 CYP19A1 SRD5A2
18 steroid catabolic process GO:0006706 9.46 SRD5A2 STS
19 positive regulation of integrin biosynthetic process GO:0045726 9.43 AR TGFB2
20 androgen metabolic process GO:0008209 9.33 CYP19A1 SRD5A1 SRD5A2
21 steroid biosynthetic process GO:0006694 9.26 CYP19A1 CYP21A2 SRD5A1 SRD5A2
22 female genitalia development GO:0030540 8.8 CYP19A1 SRD5A1 SRD5A2

Molecular functions related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.73 CYP19A1 CYP21A2 SRD5A1 SRD5A2
2 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.4 SRD5A1 SRD5A2
3 steroid hydroxylase activity GO:0008395 9.37 CYP19A1 CYP21A2
4 androgen binding GO:0005497 9.32 AR SHBG
5 3-oxo-5-alpha-steroid 4-dehydrogenase activity GO:0003865 9.26 SRD5A1 SRD5A2
6 cholestenone 5-alpha-reductase activity GO:0047751 9.16 SRD5A1 SRD5A2
7 amide binding GO:0033218 8.96 SRD5A1 SRD5A2
8 steroid binding GO:0005496 8.8 AR CYP21A2 SHBG

Sources for Alopecia, Androgenetic, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....